The Akeret or anatomical staging of neuroepithelial tumors adheres loosely to the general scheme underlying AJCC TNM staging. Like other cancer staging systems, it assists in estimating the individual prognosis, in tailoring patient-specific therapy and surveillance, and in improving the comparability of clinical research results 1.
The system is based on the prognostically critical steps along the anatomical sequence of neuroepithelial tumor progression 1.
Staging
The Akeret staging differentiates three stages in neuroepithelial tumors 1:
Akeret stage I (AS1) groups together in situ and radially confined neuroepithelial tumors
Akeret stage II (AS2) is defined by a transverse subventricular tumor spread (segmental confinement or diffuse)
Akeret stage III (AS3) clusters neuroepithelial tumors with mesenchymal CNS patterns (expansion along white matter tracts, leptomeningeal or perivascular invasion, CSF spread) or systemic metastases
History and etymology
The staging was introduced in 2021 by Swiss neurosurgeon Kevin Akeret and his colleagues as the "anatomical staging system of neuroepithelial tumors" 1.
Unable to process the form. Check for errors and try again.